SARS-CoV-2 screening device of Assistance Publique des Hôpitaux de Paris (AP-HP)
Paris, 75001, France
NCT Number: NCT04578509
The investigators hypothesize that detection of SARS-CoV2 on saliva samples will increase the performance of the screening program compared to the reference strategy (RT-PCR on a nasopharyngeal swab).
Looking for future studies?
Notify MeAll sexes
Observational
Paris, 75001, France
Containment of the COVID19 pandemic relies on mass screening to allow rapid identification and isolation of cases to break transmission chains. The reference diagnostic method is based on detection of viral genomes by PCR on a nasopharyngeal swab sample (NPS).
However, the pandemic has generated a very high demand causing a shortage of specific swabs and difficulties in the supply of reagents and consumables. Nasopharyngeal sampling requires skilled personnel, and is sometimes poorly accepted by patients. These issues can reduce the quality of sampling and therefore the sensitivity of the test. This strategy also requires sending samples to specialized laboratories, generating a delay in providing results.
New diagnostic approaches on saliva samples are being developed allowing 1) an easier sampling procedure and 2) a diagnostic technique that can be performed in point-of-care.
Previous evaluations suggest that these approaches have a lower sensitivity than the reference strategy (PCR on NPS), around 50 to 90% depending on the technique used.
Despite lower sensitivity compared to the reference strategy, the investigators hypothesize that detection of SARS-CoV2 on saliva samples will improve the performance of the screening program by considerably increasing the number of individuals tested in shorter times.
The main objective of the study is to evaluate, for the detection of SARS-CoV-2 infection, the performance of various alternative virological diagnostic strategies on saliva samples, in comparison with the reference technique (RT-PCR on NPS).
The primary endpoint of the study is positivity of the standard technique (RT-PCR on NPS) for the SARS-CoV-2 virus. The result of the alternative strategies on a saliva sample will be considered as positive or negative according to criteria specific to each of them and compared to the result of the reference technique to estimate their respective sensitivity.
The secondary objectives are to compare the diagnostic performances of RT-PCR on saliva versus RT-PCR on NPS, the diagnostic performances of alternative techniques on saliva versus RT-PCR on saliva, to evaluate the acceptability of the saliva self-sampling and the cost-effectiveness of new diagnostic strategies compared to the reference technique.
The study will include adults and children in whom a NPS is performed for SARS-CoV-2 screening. After informed consent, participants will be asked to provide a saliva sample before nasopharyngeal sampling. Both samples will be analyzed in parallel. The analytical performance of each technique will be assessed, centrally or delocalised, depending on the feasibility of the techniques and according to the advice of the scientific board. The analyzes will be carried out by a team of technicians specifically recruited for the study. All samples collected will be stored in a centralized in a biobank.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test
Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach
Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.
Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected
Time frame: At diagnosis
RT-PCR on nasopharyngeal is considered as gold standard
Time frame: At diagnosis
Time frame: At diagnosis
Time frame: At diagnosis
Time frame: At diagnosis
Number of samples tested in a day for each test
Time frame: At diagnosis
Quantity of premises required for each test
Time frame: At diagnosis
Feasibly Reading and interpretation For each test
Time frame: At diagnosis
Render times for each test
Time frame: At diagnosis
Research of IgG by ELISA and RDT
Time frame: At diagnosis
Research of IgM by ELISA and RDT
Time frame: At diagnosis
Research of IgA by ELISA and RDT
Time frame: At diagnosis
Time frame: At diagnosis
Evaluation by questionnaire of the patient tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions are about pain, discomfort, speed of performance)
Time frame: At diagnosis
Evaluation by questionnaire of the operator tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions is about pain, discomfort, speed of performance)
Time frame: At diagnosis
Including sampling, transport, technique (consumables, reagents, machine), human resources
Assistance Publique - Hôpitaux de Paris
Other
Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva (COVID-19)
Acronym: SALICOV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07079670
COVID-19, Coronaviridae Infections
Phoenix, Arizona, United States
View Trial DetailsNCT07069309
COVID-19, Coronaviridae Infections
Walnut Creek, California, United States
View Trial DetailsNCT05997290
COVID-19, Coronaviridae Infections
Athens, Alabama, United States
View Trial DetailsNCT05168813
Blood-Borne Infections, COVID-19
Gaborone, Botswana
View Trial Details